Journal Article Review Epublish 7 citations
PubMed: 38026157 DOI: 10.1016/j.isci.2023.108192
Advances and challenges of immunotherapies in NK/T cell lymphomas.
iScience 26(11):108192
Authors: Ling He, Na Chen, Lei Dai, Xingchen Peng
Affiliations
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041, China. School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan 610500, China.
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041, China.
Abstract
Natural killer (NK)/T cell lymphoma (NKTCL) is a rare subtype of Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma characterized by poor clinical outcomes. It is more common in East Asian and Latin American countries. Despite the introduction of asparaginase/pegaspargase-based chemotherapy, the prognosis of patients with advanced NKTCL needs to be improved, and few salvage treatment options are available for relapsed/refractory patients who fail chemotherapy. Although many unknowns remain, novel treatment strategies to further improve outcomes are urgently needed. Immunotherapy has emerged and shown favorable antitumor activity in NKTCL, including monoclonal antibodies targeting immune checkpoint inhibitors, other receptors on the cellular membrane, and cellular immunotherapy, which could enhance immune cells attack on tumor cells. In this review, we provide an overview of recent immunotherapy in NKTCL, focusing on programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), chimeric antigen receptor (CAR) TÂ cells, EBV-specific cytotoxic T lymphocytes, immunomodulatory agents, and other targeted agents, as well as the current progress and challenges in the field.
MeSH
Lymphoma, T-Cell, Immunotherapy, Cells, Cell Death, Neoplasms, Lymphoma, Non-Hodgkin, Herpesvirus 4, Human, T-Lymphocytes, Cytotoxic, Chemotherapy
Cited by
- Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma. Oncol Res, 2025
- The small molecule drug CBL0137 interferes with DNA damage repair and enhances the sensitivity of NK/T-Cell lymphoma to cisplatin. Cancer Biol Ther, 2025
- Carcinogenic mechanisms of virus-associated lymphoma. Front Immunol, 2024
- A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia. Blood, 2024
- p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma. Discov Oncol, 2025
- Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis. Front Immunol, 2025
- Orbital natural killer/T-cell lymphoma: a comprehensive case series and literature review. BMC Cancer, 2025
- Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis. BMC Cancer, 2025